Financial Performance - The company's operating revenue for Q1 2024 was CNY 321,582,715.19, representing a decrease of 16.32% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 86,013,453.60, down 29.22% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 82,736,693.46, a decrease of 17.71% compared to the previous year[5]. - The basic and diluted earnings per share were both CNY 0.17, reflecting a decline of 29.17% year-on-year[5]. - Total operating revenue for Q1 2024 was ¥321,582,715.19, a decrease of 16.3% compared to ¥384,316,306.14 in Q1 2023[25]. - Net profit for Q1 2024 was ¥87,436,875.95, down 29.7% from ¥124,371,119.11 in Q1 2023[26]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.17, compared to ¥0.24 in Q1 2023[27]. Cash Flow - The net cash flow from operating activities increased significantly by 397.71%, amounting to CNY 67,114,506.07[5][10]. - Cash flow from operating activities generated a net inflow of ¥67,114,506.07, significantly up from ¥13,484,563.45 in the same period last year[30]. - Cash flow from investing activities resulted in a net outflow of ¥100,419,774.08, compared to a net inflow of ¥103,596,691.92 in Q1 2023[30]. - Cash flow from financing activities showed a net outflow of ¥32,994,084.94, worsening from a net outflow of ¥26,790,759.52 in Q1 2023[30]. - The net increase in cash and cash equivalents for Q1 2024 was -$65,889,106.33, compared to an increase of $88,332,104.53 in the same period last year[31]. - The ending balance of cash and cash equivalents for Q1 2024 was $417,286,545.60, down from $732,976,882.93 in the previous year[31]. - The beginning balance of cash and cash equivalents was $483,175,651.93, indicating a decrease in available cash[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,788,151,087.27, a slight increase of 0.44% from the end of the previous year[6]. - Total current assets as of March 31, 2024, amounted to CNY 2,021.27 million, down from CNY 2,151.18 million at the end of 2023[21]. - Total liabilities decreased from CNY 1,030.38 million at the end of 2023 to CNY 963.62 million as of March 31, 2024[22]. - The company's total assets as of March 31, 2024, were CNY 3,788.15 million, slightly up from CNY 3,771.63 million at the end of 2023[21]. - Shareholders' equity attributable to the parent company increased by 3.39% to CNY 2,646,087,081.99[6]. Operational Highlights - In Q1 2024, the company's self-produced products generated revenue of CNY 260.60 million, a year-on-year decrease of 6.56% due to last year's high base[17]. - The core product Getein1600 shipped over 130 units in Q1, maintaining the company's leading position in the POCT field[17]. - The small luminescence products (MAGICL6000 + MAGICL6000i) saw a shipment of over 220 units in Q1, with MAGICL6000i accounting for nearly 90 units, resulting in a revenue increase of 58.42% for the chemiluminescence line, totaling CNY 68.41 million[17]. - The Metis6000 fully automated immunoassay production line was launched in Q1 2023, with nearly 30 units installed in Q1 2024, bringing the total to nearly 100 units, over 50% of which are in secondary hospitals[18]. - The company continues to focus on regular business operations and market expansion while enhancing cost control and efficiency[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,655[12]. - The company has not reported any changes in the borrowing or lending of shares among major shareholders during the reporting period[16]. Expenses - Total operating costs decreased by 16.3% to ¥220,695,492.33 from ¥263,733,676.37 year-over-year[25]. - Research and development expenses decreased to ¥44,003,300.95, down 20.2% from ¥55,164,547.70 year-over-year[25]. - Sales expenses slightly decreased to ¥66,563,839.18 from ¥68,703,246.56 in Q1 2023[25]. - The company reported a significant increase in other income to ¥6,877,977.00 from ¥11,258,800.02 in the previous year[25]. Return on Equity - The weighted average return on equity decreased by 1.48 percentage points to 3.30%[6].

证券代码：603387 证券简称：基蛋生物 公告编号：2024-015 基蛋生物科技股份有限公司 关于召开 2023 年度暨 2024 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024年5月21日（星期二）下午14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadsho w.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2024年5月14日（星期二）至5月20日（星期一）16:00前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱IR@getein.cn 进行提问。公司将通过本次业绩说明会，在信息披露允许范围内对投资者普遍 关注的问题进行回答。 基蛋生物科技股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日披 露了公司 2023 年年度报告及 2024 年第一季度报告，为便于广大投资者更全面深 入地了解公司 2023 年度及 2024 年第一季度经营成果、财 ...

Financial Performance - In 2023, the company achieved a net profit of RMB 284,080,449.03, with a net profit attributable to shareholders of RMB 279,771,914.08, representing a profit distribution ratio of 36.25%[5][7]. - The company's operating revenue for 2023 was ¥1,369,162,256.52, a decrease of 24.85% compared to ¥1,821,860,703.15 in 2022[22]. - Net profit attributable to shareholders decreased by 43.92% to ¥279,771,914.08 from ¥498,909,980.40 in the previous year[24]. - Basic and diluted earnings per share fell to ¥0.55, down 43.88% from ¥0.98 in 2022[23]. - The cash flow from operating activities decreased by 31% to ¥333,220,661.81, compared to ¥482,957,526.77 in 2022[24]. - The company's total assets increased by 2.52% to ¥3,771,626,052.94 at the end of 2023, up from ¥3,678,885,572.13 at the end of 2022[22]. - The weighted average return on equity decreased by 10.59 percentage points to 11.17% from 21.76% in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥241,487,200.13, a decrease of 47.68% from ¥461,538,014.58 in 2022[22]. - The company's total distributable profit for 2023 was RMB 1,508,000,016.03, after accounting for the retained earnings and cash dividends paid in 2022[5]. - The company's total distributable profit for the parent company in 2023 was RMB 1,240,680,112.38, after accounting for retained earnings and cash dividends[5]. Dividend Distribution - The company proposed a cash dividend of RMB 1 per 10 shares, amounting to a total cash dividend distribution of RMB 50,715,351.70 based on the total share capital of 507,153,517 shares[6]. - The total cash dividend amount for the year is CNY 101,430,703.40, accounting for 36.25% of the net profit attributable to ordinary shareholders in the consolidated financial statements[175]. - The company plans to distribute at least 30% of the average annual distributable profit over the last three years as cash dividends[167]. - The company has a cash dividend policy that stipulates a minimum of 10% of the distributable profit will be distributed as cash dividends if there are no major investment plans or cash expenditures[167]. Research and Development - The company plans to continue its focus on research and development of new products and technologies to enhance market competitiveness[8]. - R&D investment for the reporting period was 266 million yuan, accounting for 19.40% of the operating revenue[38]. - The company has established eight major technology platforms in the IVD field, expanding its product range from low-throughput to high-throughput solutions[82]. - The company aims to enhance its R&D capabilities and product lineup, focusing on a "production generation, R&D generation, and reserve generation" strategy for innovation[122]. - The company plans to increase R&D investment in high-speed fully automated immunoassay analyzers and nucleic acid POCT products, aiming to maintain its leading position in the POCT market[122]. Market Expansion - The company is expanding its overseas market presence, focusing on regions such as Europe, Asia, and Latin America, with a strategy to promote its products in local markets[39]. - The company has established wholly-owned subsidiaries in Hong Kong, Singapore, and Germany, with plans to set up offices in Southeast Asia, South Asia, and Africa in 2024 to enhance local market penetration[123]. - The company aims to expand its market reach from grassroots medical institutions to higher-tier hospitals and international markets, establishing a multi-channel sales system[54]. - The company is set to focus on three major product line strategies: multi-level POCT products, innovative production line products, and nucleic acid POCT strategy[120]. Product Development - The company launched the MAGICL 6000i, which has a testing speed of 200T/h, enhancing its competitive position in the small chemiluminescence market[35]. - The company launched 15 new testing kits, including 1 for inflammation, 3 for cardiovascular diseases, 2 for rheumatology, and various others, utilizing fluorescence immunochromatography and chemiluminescence methods[56]. - The company has registered 74 new reagent products in 2023, including 14 in the POCT field and 23 in the chemiluminescence field, reflecting ongoing product development and market expansion efforts[55]. - The company is focusing on home testing reagents for disease screening and management, targeting common diseases such as diabetes, hypertension, and heart disease[76]. Compliance and Governance - The company's financial report has been audited by Gongzheng Tianye Accounting Firm, which issued an unqualified opinion with emphasis on certain matters[4]. - The company maintains independent financial operations with a dedicated finance department and a separate accounting system, ensuring compliance with regulations[135]. - The company has a comprehensive internal control system covering various financial management aspects, including related party transactions and external guarantees[135]. - The company has not faced any penalties from securities regulatory agencies in the past three years, indicating compliance with regulations[153]. Environmental Responsibility - The company has achieved compliance with the wastewater discharge standards, with TP and NH3-N levels meeting the B grade standards of GB/T31962-2015[185]. - The company has implemented a rainwater separation system, with all rainwater being collected and directed to the municipal rainwater drainage system[185]. - The company reported a total investment of CNY 1.32 million in social responsibility initiatives, including donations to various charitable foundations[190]. - The company has taken measures to reduce carbon emissions, focusing on energy-saving practices and the use of environmentally friendly equipment[190]. Risk Management - The company has outlined various risk factors that may impact its future development strategies and operational goals, with corresponding mitigation measures[9]. - The company has implemented risk control measures for foreign exchange hedging, including only engaging with large banks for transactions[114]. - The company faces risks from industry policy changes and price pressures due to centralized procurement, which could impact its operations if not addressed[126]. Shareholder Engagement - The company has established effective communication channels with investors to ensure equal treatment and transparency[132]. - The company has a complete decision-making process for profit distribution, ensuring the involvement of independent directors and minority shareholders[172]. - The company plans to implement a three-year shareholder return plan from 2023 to 2025, emphasizing commitment to shareholder value[158].

一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 15 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 221,611,682 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 43.6971 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 证券代码：603387 证券简称：基蛋生物 公告编号：2024-005 基蛋生物科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 本次股东大会由公司董事会召集，由公司董事长苏恩本主持。本次股东大会 采用现场投票和网络投票相结合的方式进行表决。会议的召集、召开、表决形式 (一) 股东大会召开的时间：2024 年 1 月 16 日 (二) 股东大会召开的地点：南京市六合区沿江工业开发区博富路 9 号基蛋生 物科技股份有限公司四楼会议室 (三) 出席会议的普通股股东 ...

基蛋生物科技股份有限公司 第四届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届董事会第一次会议于 2024 年 1 月 16 日在公司会议室以现场结合通讯表决方式召开，会议通知于 2024 年 1 月 16 日以电话方式送达，根据《公司章程》和公司《董事会议事规则》的有关规定，本次董 事会会议豁免通知时限要求。会议应到董事 9 人，实到董事 9 人。本次会议由董事推举 的召集人苏恩本先生主持。本次会议召集、召开符合《中华人民共和国公司法》及有关 法律、法规和《公司章程》的规定。 二、董事会会议审议情况 会议审议并通过了如下议案： 证券代码：603387 证券简称：基蛋生物 公告编号：2024-002 （一）审议通过了《关于选举公司第四届董事会董事长的议案》 选举苏恩本先生为公司第四届董事会董事长，任期至公司第四届董事会任期届满。 （上述人员简历详见附件） 本项议案无需回避表决，本项议案无需提交公司股东大会审议。 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2024-001 基蛋生物科技股份有限公司 张武先生简历详见附件。 特此公告。 基蛋生物科技股份有限公司监事会 2024 年 1 月 16 日 关于选举职工代表监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（下称"公司"）第三届监事会任期已届满，根据 《公司法》、《上海证券交易所股票上市规则》、《公司章程》等有关规定，公司职 工代表大会于 2024 年 1 月 16 日下午在公司 17 号楼一楼大会议室召开，全体职工 代表出席会议，会议的召开及表决程序符合职工代表大会决策的有关规定。会议 经民主讨论、表决，全体职工代表一致通过决议如下： 一致同意选举张武先生作为公司第四届监事会职工代表监事，将与公司股东 大会选举产生的 2 名非职工代表监事共同组成公司第四届监事会，任期至第四届 监事会任期届满。 张武先生，中国国籍，无境外永久居留权，1988 年生，大专学历。2010 年至 今先后在公司担任生产操作工、组长。现担任公司制造中心办公室副主 ...

公司于股东大会同日召开了第四届董事会第一次会议及第四届监事会第一次 会议，选举产生了公司第四届董事会董事长、董事会下属各专门委员会委员、第 四届监事会主席，并聘任了公司高级管理人员及证券事务代表。现将相关情况公 告如下： 证券代码：603387 证券简称：基蛋生物 公告编号：2024-004 基蛋生物科技股份有限公司 关于董事会、监事会换届完成并聘任 高级管理人员及证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）于 2024 年 1 月 16 日召开职 工代表大会，选举张武先生担任公司第四届监事会职工代表监事；公司于 2024 年 1 月 16 日召开 2024 年第一次临时股东大会，审议通过了《关于董事会换届选举非 独立董事的议案》、《关于董事会换届选举独立董事的议案》、《关于选举监事的议 案》。至此，公司完成董事会、监事会换届选举。 一、公司第四届董事会组成情况 1、董事长：苏恩本先生； （1）战略委员会：苏恩本先生、颜彬先生、鞠熀先先生；主任委员：苏恩本 先 ...

基蛋生物科技股份有限公司 独立董事关于第四届董事会 第一次会议相关事项的独立意见 根据《公司法》、《上市公司独立董事管理办法》、《上市公司治理准 则》、《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管 指引第1号——规范运作》及《公司章程》的有关规定，我们作为基蛋生物科技 股份有限公司（以下简称"公司"）的独立董事，基于独立客观的立场，本着审 慎负责的态度，我们仔细核查了公司第四届董事会第一次会议审议事项的相关 资料、实施及决策程序，发表如下独立意见： 1、同意聘任苏恩本先生为公司董事长、总经理；同意聘任颜彬先生、孔婷 婷女士先生为公司副总经理；同意聘任倪文先生为公司财务总监；同意聘任刘葱 女士为公司董事会秘书；同意聘任谢玉鑫先生为公司证券事务代表； 2、被聘任人员的提名、聘任程序符合有关法律、法规及《公司章程》的规 定； 4、本次聘任人员是在充分了解被聘任人员的资格条件、教育背景、工作经 历、管理经验、业务专长等情况的基础上进行的，被聘任人员具备履行职责所必 须的专业或行业知识，不存在法律法规、规范性文件规定的不得担任高级管理人 员的情形。 凌 华: (此页无正文,为《基蛋生物科技股份有限公 ...

上海市锦天城（南京）律师事务所 关于基蛋生物科技股份有限公司 2024年第一次临时股东大会的 法律意见书 地址：南京市建邺区江东中路 347 号国金中心一期 27、28 楼 电话：025-68515000 传真：025-68516601 邮编：210019 上海市锦天城（南京）律师事务所 法律意见书 上海市锦天城（南京）律师事务所 上海市锦天城（南京）律师事务所 法律意见书 关于基蛋生物科技股份有限公司 2024年第一次临时股东大会的 法律意见书 致：基蛋生物科技股份有限公司 上海市锦天城（南京）律师事务所（以下简称"本所"）接受基蛋生物科技股 份有限公司（以下简称"公司"）委托，就公司召开2024年第一次临时股东大会（以 下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称《公司法》）、《上市公司股东大会规则》等有关法律、法规、规范性文件以及 《基蛋生物科技股份有限公司章程》（以下简称《公司章程》）的有关规定，出具 本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务管 理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行了法 定职责，遵 ...

第四届监事会第一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、监事会会议召开情况 基蛋生物科技股份有限公司 基蛋生物科技股份有限公司（以下简称"公司"）第四届监事会第一次会议于2024 年1月16日在公司会议室以现场表决方式召开，会议通知于2024年1月16日以电话方式送 达，根据《公司章程》和公司《监事会议事规则》的有关规定，本次监事会会议豁免通 知时限要求。会议应到监事人3人，实到监事3人；公司董事会秘书列席了本次监事会会 议。 会议由监事共同推举的李靖女士召集和主持。本次会议召集、召开符合《中华人民 共和国公司法》及有关法律、法规和《公司章程》的规定。 二、监事会会议审议情况 证券代码：603387 证券简称：基蛋生物 公告编号：2024-003 （一）审议并通过了《关于选举李靖为公司第四届监事会主席的议案》 公司监事会对《关于选举李靖为公司第四届监事会主席的议案》进行全面了解和审 核后认为： 李靖女士具备履行职责所必需的专业知识和工作经验，具备相应的组织、监督和协 调能力，具备良好 ...